top of page
Landing page header.png

Investment Opportunity in Nanotechnology-based Cancer Drug Development

The private placement round is open until the end of November 2024

ABOUT iNANOD

iNANOD AS is a privately owned start-up company grown through the pull mechanism of innovation from the Oslo Cancer Cluster Incubator. iNANOD utilizes nano-biotechnology to establish a platform to improve drug delivery, especially within oncology. It has the ambition to deliver the active pharma ingredient in a targeted and accelerated way while generating immunotherapy. Therefore envisioning to kill cancer cells target-specifically by combined double actions of chemo and immunotherapy in solid malignant tumours.

THE PROBLEM

As per the World Health Organization, 9.6 million people died from cancer in 2018 (1 out of 6 deaths worldwide). Today, cancer patients suffer from a high rate of undesired side effects while under chemotherapy. Most cancer drugs are not site-specific.

 

Max 0.2% of small molecule cancer drugs reach cancer cells, while the rest spread over the body and impart unintended adverse effects on healthy cells.

iNANOD (4).png

THE SOLUTION

NANOparticle2bw.jpg

An innovative platform technology for cancer drug-delivery with the potential to disrupt the cancer drugs market.

​

iNANOD's technology combines individually proven technologies to improve drug delivery and reduce side effects.

​

We detected the need to incorporate cutting-edge technology in modern cancer treatments and aims to add value by introducing accelerated uptake involving a time parameter.

​

Our objective is to develop a platform technology for shorter chemotherapy with fewer side effects.

OUR PROPOSAL

THE TEAM

Portrait_004_Ã…ge_Master.jpg

Åge Nærdal

Chairman

Linkedin icon.png

Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.

stener-kvinsland profil bilde_edited_edited.jpg

Stener Kvinnsland

Board member

Linkedin icon.png

MD with a PhD in oncology. Various roles in the pharmaceutical and biotech industry, former COB at Oslo University Hospital, former MD of Helse Bergen and former Director at Haukeland University Hospital. Specialist and professor in cancer medicine.

Per.jpg

Per Foss

Board member

Linkedin icon.png

Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.

Nalinava3.jpg

Nalinava Sengupta

Board Member & CEO

Linkedin icon.png

After 15 years of academic research in chemistry, turned entrepreneur for a mission.

WhatsApp Image 2022-12-12 at 15_edited.jpg

Thomas Due

Board member

Linkedin icon.png

He has over 20 years of Innovation and Venture Capital Fundraising experience in Norway. He has spent most of his adult life working where finance meets entrepreneurs. 

ADVISORS

Knut.jpg

Knut Smerud

Advisory Board Member

Linkedin icon.png

-

Tanima4.jpg

Tanima Sengupta

Advisory Board Member

Linkedin icon.png

Co-founder and is a senior scientist in Norwegian Air Research Institute

11039Gokce-110 h_Edit.jpg

Gokce Ataman

Financial Advisor

Linkedin icon.png

Senior finance professional with over 15 years of experience in M&A advisory and asset management.

Jørn.jpg

Jørn Lein-Mathisen

Business Development Advisor

Linkedin icon.png

Business angel. Business development and entrepreneurial experiences internationally over 28 years.

Hilde2.jpg

Hilde Nilsen

Board member 

Linkedin icon.png

Head of researchDepartment of Microbiology, Oslo University Hospital

Espen.jpg

Espen Burum-Auensen

Advisory Board Member

Linkedin icon.png

Medical doctor with a PhD in the field of oncology. Various roles in the pharmaceutical and biotech industry including business development, clinical trial development, commercial operations, and medical affairs.

Portrait_003_Ketil_Master.jpg

Ketil Wig

Strategic Advisor

Linkedin icon.png

An expert in strategy and corporate finance advisory, has executed and negotiated hundreds of projects and transactions within strategy and M&A and restructurings / turnarounds.

Portrait_001_Ukjent_Master.jpg

Hilde Morris

Scientific Advisor

Linkedin icon.png

Studied veterinary medicine and led international clinical development programs. Advices iNANOD for pre-clinical research, management, and corporate governance.

Foto Bruno Pirovino (1)_edited_edited.jpg

Bruno Pirovino-Zuercher

Fund-raising Advisor

Linkedin icon.png

Finance Executive with over 25 years of experience in global LifeScience organisations and start/scale-up companies; Angel Investor

SUPPORTERS

362ee937-ec3f-477c-afa9-568899afa683-w_9
IN_Logo.png
OIH Logo.jpg

MEMBER OF

Logo-OCC.png
Logo_OCC_I_E_lang_cmyk.png
LifeScience_4.png

SUBCONTRACTORS

Nordic Biosite Logo.jpg
image.png
image_edited.png

FUNDRAISING ROUND AND PURPOSE

iNANOD is raising USD 1.4 million at a pre-money valuation of USD 4.0 million. 

​

The Company previously raised ca. USD 0.5 million led by business angels.

​

In this round, iNANOD is selling shares at a price of  USD 1.08 per share.

Inanod-SoMe-kampanje2.webp

If iNANOD is successful in reaching PoP, the Company will engage in further fundraising to fund regulatory preclinical development, phase I and phase II clinical trials, with a view to entering into a licensing deal with Big Pharma after phase IIb. A typical licensing deal includes an upfront payment, milestone payments, and royalty fees.

CONTACT

TAKE THE NEXT STEP

For detailed information please get in

touch with iNANOD at:

If you’re interested in investing in iNANOD, please enter your contact information below. We’ll get in touch with you.

iNANOD AS c/o VENTURELAB

Nedre Skøyen vei 11,

Oslo, Norway 

0276

+47 938 13 586

bottom of page